Paresh Patel, MD
Gastroenterology · Kansas City, MONPI 1386750073
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.6% of the total across 157 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by AbbVie at 35.3% of the total. 2025 is the largest year on record at $673, 2.4 times the $282 reported in 2019.
Across 157 payments — averaging $21.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Pfizer$500
- Medtronic$485
- Johnson & Johnson$410
- Janssen Scientific Affairs, LLC$110
- Celltrion USA Inc.$103
- plus $561 from 20 others
Across 2 payments — averaging $25,713 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$35K
- Ardelyx, Inc.$16K
What the payments were for
- Food & beverage$3,10393%
- Education$2477%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 70 | $1,181 |
| Pfizer | 37 | $500 |
| Medtronic | 6 | $485 |
| Johnson & Johnson(2 entities) | 7 | $410 |
| Janssen Scientific Affairs, LLC | 1 | $110 |
| Celltrion USA Inc. | 6 | $103 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $93 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $58 |
| Phathom Pharmaceuticals, Inc. | 3 | $55 |
| QOL Medical, LLC | 2 | $51 |
| Mirum Pharmaceuticals, Inc. | 2 | $32 |
| Eisai Inc. | 1 | $27 |
| Digestive Care, Inc. | 1 | $26 |
| Ardelyx, Inc. | 1 | $24 |
| Nestle Healthcare Nutrition Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $21 |
| Exelixis Inc. | 1 | $20 |
| Ambu Inc. | 1 | $19 |
| Rhythm Pharmaceuticals, Inc. | 1 | $18 |
| Boston Scientific | 1 | $15 |
| Partner Therapeutics, Inc. | 1 | $15 |
| Intercept Pharmaceuticals, Inc. | 1 | $15 |
| Bristol Myers Squibb | 1 | $14 |
| Amgen | 1 | $14 |
| Abbott | 1 | $13 |
| Merit Medical Systems Inc | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,350 in reported general payments places this provider in the 65th percentile of 374 gastroenterology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cimzia (2 Pack)Certolizumab Pegol | 13 | $76,580 |
| XifaxanRifaximin | 22 | $75,762 |
| LinzessLinaclotide | 23 | $17,924 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 30 | $4,766 |
| Colestipol Hcl | 39 | $4,402 |
| Famotidine | 132 | $2,897 |
| Omeprazole | 177 | $2,614 |
| Dicyclomine Hcl | 100 | $2,244 |
| Pantoprazole Sodium | 202 | $2,027 |
| Budesonide DrBudesonide | 32 | $2,022 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 14 | $2,017 |
| Ursodiol | 25 | $1,696 |
| Azathioprine | 18 | $1,132 |
| Lactulose | 29 | $1,055 |
| CholestyramineCholestyramine (With Sugar) | 12 | $861 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu | $93 | $77,77936 claims |
| AbbVieLinzess | $1,181 | $17,92423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 374 gastroenterology providers in Missouri.
Other gastroenterology in Kansas City
- Laith Al MomaniKansas City$249K
- Ahmed SaeedKansas City$246K
- Tahar MahmoudiKansas City$114K
- Hillary BownikKansas City$85K
- Amit RastogiKansas City$63K
- Rajiv ChhabraKansas City$29K
- Bradley FreilichKansas City$26K
- Prashant PandyaKansas City$21K
- Syed JafriKansas City$20K
- Gregory MerrittKansas City$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.